ADHD Medication Reimbursements Quadruple in Ireland Over Decade
The number of patients receiving reimbursements for attention-deficit/hyperactivity disorder (ADHD) medication surged by 314 percent over a ten-year period, according to research published in the Irish Medical Journal. Authored by Anthony Maher from the University of Galway’s School of Psychology, the study reveals that public scheme prescription counts jumped from 3,377 patients in 2015 to 13,966 patients by 2024, reflecting an expansive shift in how adult neurodevelopmental conditions are diagnosed and managed in clinical practice.
- Dosage units of ADHD medication dispensed to adults through public schemes more than doubled between 2015 and 2024.
- Young adults aged 16 to 34 and female patients experienced the largest demographic growth during the decade.
- Public reimbursement data covers roughly 40 percent of the population, indicating that overall prescription volumes across private payers are likely higher.
Growth in Adult Prescriptions and Demographic Shifts
The research tracks public scheme reimbursements under the Drugs Payment Scheme and the General Medical Services Scheme. Total dosage units—meaning individual tablets or capsules spanning strengths from 10mg to 70mg—increased by 211 percent, moving from 700,574 units in 2015 to 2,217,634 units in 2024. The data demonstrates a steep acceleration in specific pharmaceutical agents, with units of lisdexamfetamine rising by 504 percent from 59,088 to 356,641 between 2020 and 2023.
Demographic distribution shifted notably over the decade. Patients aged 16 to 34 recorded the largest expansion in treatment rates. The volume of female patients grew substantially, nearly equalising with male patient counts over the ten-year timeframe. This convergence aligns with broader clinical recognition that ADHD frequently persists into adulthood, with a worldwide adult prevalence estimated between 2 percent and 3 percent.
Diagnostic Visibility Versus Overdiagnosis Concerns
Historically understood primarily as a childhood neurodevelopmental disorder affecting attention, impulse control, and decision-making, ADHD presents differently across demographics. Adult diagnoses have climbed as clinical awareness of these varied presentations improves. Maher noted that the reimbursement data provides a partial representation rather than an exhaustive count, pointing out as a working pharmacist that the proportion of dispensed medication does not directly dictate the total underlying prevalence of the condition.
These findings mirror parallel epidemiological investigations in other jurisdictions. Research published earlier in the year by the University of Southampton found an increase in actual clinical diagnoses between 2000 and 2018. However, the UK authors concluded that diagnosis rates remain substantially below estimated population prevalence levels, offering no current evidence that ADHD is overdiagnosed at a population level.
Regional Expansion and Healthcare Access Infrastructure
Geographic analysis of the reimbursement figures reveals pronounced increases in rural regions. North Cork registered the highest patient growth at 437 percent, climbing from 38 patients to 204 patients, followed by Waterford, Cork South Lee, and Sligo/Leitrim. Maher attributed these shifts to increased public awareness and a reduction in societal stigma surrounding clinical assessments and pharmacotherapy.
The surge coincides with structural strain on healthcare delivery models. Ireland’s public adult ADHD service launched in 2021 and experienced rapid capacity constraints, prompting a rise in private diagnostic and treatment providers. For individuals seeking formal clinical evaluation or ongoing pharmacological management for persistent neurodevelopmental symptoms, consulting with qualified psychiatrists, clinical psychologists, or specialized medical practitioners remains the standard pathway to establish an accurate diagnosis and individualized care plan.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.